Phase 1 study of napabucasin, a cancer stemness inhibitor, in patients with advanced solid tumors
Open Access
- 1 May 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cancer Chemotherapy and Pharmacology
- Vol. 85 (5), 855-862
- https://doi.org/10.1007/s00280-020-04059-3
Abstract
Purpose Napabucasin is a cancer stemness inhibitor that targets a number of oncogenic pathways, including signal transducer and activator of transcription 3 (STAT3). Phase 1/2 studies suggest tolerability and anti-tumor activity in various types of cancer; a Phase 3 study of napabucasin plus standard therapy in colorectal cancer is ongoing. This is a Phase 1 dose-escalation study in patients with advanced solid tumors, and the first study of napabucasin in Japanese patients. Methods Patients received napabucasin 480, 960, or 1440 mg daily in 28-day cycles until disease progression or intolerable toxicity. Primary objectives were to determine dose-limiting toxicities (DLTs), maximum tolerated dose (MTD), and the pharmacokinetic (PK) profile of napabucasin. Blood samples were taken for PK analysis on Days 1, 2, 8, and 15 of Cycle 1, and Days 29 and 30 of Cycle 2. Secondary objectives were to assess napabucasin antitumor activity, and the relationship between biomarkers and antitumor activity. JapicCTI-No: JapicCTI-132152. Results Enrolled were 14 patients (480 mg [n = 3], 960 mg [n = 4], 1440 mg [n = 7]). One patient experienced a DLT (Grade 3, anorexia). MTD was 1440 mg/day. Most common drug-related adverse events were diarrhea (n = 9), nausea (n = 4), vomiting (n = 3), and anorexia (n = 3). Napabucasin showed a similar PK profile to previous studies and no abnormal accumulation was observed. Following treatment, two patients had stable disease; the remaining 12 had progressive disease. Conclusion Napabucasin was well-tolerated at doses up to 1440 mg/day in Japanese patients with advanced solid tumors; the PK profile was comparable to that reported previously.Keywords
Funding Information
- Sumitomo Dainippon Pharma
This publication has 28 references indexed in Scilit:
- Suppression of prostate cancer progression by cancer cell stemness inhibitor napabucasinCancer Medicine, 2016
- Multiple regulation pathways and pivotal biological functions of STAT3 in cancerScientific Reports, 2015
- Suppression of cancer relapse and metastasis by inhibiting cancer stemnessProceedings of the National Academy of Sciences of the United States of America, 2015
- Targeting the STAT3 signaling pathway in cancer: Role of synthetic and natural inhibitorsBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2014
- Drug-repositioning screening identified piperlongumine as a direct STAT3 inhibitor with potent activity against breast cancerOncogene, 2014
- -catenin is constitutively active and increases STAT3 expression/activation in anaplastic lymphoma kinase-positive anaplastic large cell lymphomaHaematologica, 2010
- STAT3 upregulates the protein expression and transcriptional activity of β-catenin in breast cancer.2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal Of Cancer, 2009
- The Biology of Cancer Stem CellsAnnual Review of Cell and Developmental Biology, 2007
- Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cellNature Medicine, 1997